Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: Report of two cases

Simona Gurzu, Zoltan Kadar, Tivadar Bara, Tivadar Jr. Bara, Adrian Tamasi, Leonard Azamfirei, Ioan Jung

Mixed adenoneuroendocrine carcinoma (MANEC) is a rare tumor of the gastrointestinal tract that consists of a dual adenocarcinomatous and neuroendocrine differentiation, each component representing at least 30% of the tumor. To date, only seven cases have been reported in the cecum, and less than 40 in the stomach. Our first case was diagnosed in a 74-years-old female as a polypoid lesion of the cecum with direct invasion in the transverse colon, without lymph node metastases. The second case was diagnosed in the stomach of a 46-years-old male as a polypoid tumor of the antral region that invaded the pancreas and presented metastases in 22 regional lymph nodes. The metastatic tissue was represented by the glandular component. In both cases, the tumor consisted of a moderately-differentiated tubular adenocarcinoma (with mucinous component in Case 1) intermingled with neuroendocrine carcinoma. Ki67 index was lower than 20% in Case 1, respectively higher than 20% in Case 2. The neuroendocrine component was marked by synaptophysin and neuron specific enolase, being negative for Keratins 7/20. The neuroendocrine component represented 60% in Case 1, and 40% in Case 2, respectively. The glandular components were marked by carcinoembryonic antigen, maspin and keratin 20/7 (Case 1/2). Both cases were proved to be microsatellite stable. Independently by the localization and tumor stage, MANECs appear to be highly malignant tumors, with high risk for distant metastases. The aggressiveness seems to depend on the endocrine component, independent of its proportion. The neuroendocrine component could be a dedifferentiated adenocarcinoma with a neuroendocrine phenotype.

Key words: Mixed adenoneuroendocrine carcinoma; Composite tumor; Mixed tumor; Colorectal; Stomach; Cecum; Maspin; Carcinoembryonic antigen; Keratin 7; Keratin 20

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: The aim of this paper was to report the clinicopathological data of two cases of mixed adenoneuroendocrine carcinomas (MANECs), one in the cecum and one in the stomach. MANEC is a rare tumor of the gastrointestinal tract that consists of a dual adenocarcinomatous and neuroendocrine differentiation. To date, only seven cases have been reported in the cecum, and less than 40 in the stomach. The characteristics of these cases, in correlation with data from literature, proved that MANEC is a highly malignant tumor, its aggressiveness being related to the endocrine component, independent of its proportion.

Gurzu S, Kadar Z, Bara T, Bara TJ, Tamasi A, Azamfirei L, Jung I. Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: Report of two cases. World J Gastroenterol 2015; 21(4): 1329-1333 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i4/1329.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i4.1329

INTRODUCTION
The term mixed adenoneuroendocrine carcinoma (MANEC) was introduced by the World Health Organization in 2010 referring to a neoplasm with dual adenocarcinomatous and neuroendocrine differentiation, each component representing at least 30% of the tumor[1]. Before 2010, this tumor was reported as a mixed or composite tumor[2]. It should be distinguished from the collision tumor, in which the two components are closely juxtaposed but not admixed, and the amphi­chrine tumor with dual endocrine and exocrine differentiation within the same cell[1,2]. Diagnosis is mainly based on the tumor architecture, being completed by the immunostains with specific neuroendocrine markers such as chromogranin, synaptophysin, CD56, and neuron­specific enolase (NSE), combined with the markers on non­endocrine glandular component and slightly positive in the neuroendocrine areas (Figure 1). In the ascending colon, the glandular component represented about 40% of the tumor, being marked by synaptophysin and NSE, which did not display positivity for keratin AE1/AE3, keratins 7/20, CEA, and chromogranin. A low mitotic activity was seen (< 20 mitoses/10 HPFs). Among these tumor clusters, moderately differentiated glandular structures with focal intraluminal Alcian blue­positive mucus were also seen. The glandular component represented about 40% of the tumor, being marked by keratin AE1/AE3, keratin 20, and CEA, without positivity for chromogranin, synaptophysin, NSE, and keratin 7. Ki67 proliferative index was < 20% (G2), without differences among the two components. Maspin expression was cytoplasmic in the glandular component and slightly positive in the neuroendocrine areas (Figure 1). In the ascending colon, an adenomatous polyp without dysplasia was associated.

The molecular examinations, performed with Roche’s LightCycler PCR­ and melting­point analysis, revealed a stable microsatellite status. MLH­1 and MSH­2 were positive in both tumor components.

Based on the tumor stage, a classical FOLFOX therapy was recommended. The postoperative course was uneventful, and to date, the patient has survived 10 mo without any evidence of recurrence or metastases.

CASE REPORT
Case 1
A 74­years­old female was admitted to the hospital with intestinal obstruction symptoms, and an emergency right hemicolectomy with terminal ileum resection was performed. Gross examination of the surgical specimen revealed a 70 mm × 18 mm polyoid tumor that produced obstruction of the cecum and presented direct invasion in the serosa of the transverse colon, without invasion in the appendix. The proximal and distal resected margins were free from tumor involvement. Histopathological examination of the surgical specimen confirmed the tumor infiltration of the transverse colon, without metastases in the 40 regional lymph nodes. Angiolympathic invasion, without perineural invasion, was also noted (pT4bN0 stage). The tumor architecture was predominantly (60% of tumor) solid, consisting of clusters of monomorphic tumor cells with abundant cytoplasm and large nuclei, marked by synaptophysin and NSE, which did not display positivity for keratin AE1/AE3, keratins 7/20, CEA, and chromogranin. A low mitotic activity was seen (< 20 mitoses/10 HPFs). Among these tumor clusters, moderately differentiated glandular structures with focal intraluminal Alcian blue­positive mucus were also seen. The glandular component represented about 40% of the tumor, being marked by keratin AE1/AE3, keratin 20, and CEA, without positivity for chromogranin, synaptophysin, NSE, and keratin 7. Ki67 proliferative index was < 20% (G2), without differences among the two components. Maspin expression was cytoplasmic in the glandular component and slightly positive in the neuroendocrine areas (Figure 1). In the ascending colon, an adenomatous polyp without dysplasia was associated.

The molecular examinations, performed with Roche’s LightCycler PCR­ and melting­point analysis, revealed a stable microsatellite status. MLH­1 and MSH­2 were positive in both tumor components.

Case 2
A 46­years­old male was admitted to the hospital with symptoms suggesting gastric cancer: weight loss, hematemesis and melena, without signs of carcinoid syndrome. On upper gastrointestinal endoscopy, a type I­Borrmann’s tumor was described in the antral region, which was surgically removed. Intraoperatively, direct invasion in the

Gastrointestinal MANEC

Core tip: The aim of this paper was to report the clinicopathological data of two cases of mixed adenoneuroendocrine carcinomas (MANECs), one in the cecum and one in the stomach. MANEC is a rare tumor of the gastrointestinal tract that consists of a dual adenocarcinomatous and neuroendocrine differentiation. To date, only seven cases have been reported in the cecum, and less than 40 in the stomach. The characteristics of these cases, in correlation with data from literature, proved that MANEC is a highly malignant tumor, its aggressiveness being related to the endocrine component, independent of its proportion.

Gurzu S, Kadar Z, Bara T, Bara TJ, Tamasi A, Azamfirei L, Jung I. Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: Report of two cases. World J Gastroenterol 2015; 21(4): 1329-1333 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i4/1329.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i4.1329

INTRODUCTION
The term mixed adenoneuroendocrine carcinoma (MANEC) was introduced by the World Health Organization in 2010 referring to a neoplasm with dual adenocarcinomatous and neuroendocrine differentiation, each component representing at least 30% of the tumor[1]. Before 2010, this tumor was reported as a mixed or composite tumor[2]. It should be distinguished from the collision tumor, in which the two components are closely juxtaposed but not admixed, and the amphi­chrine tumor with dual endocrine and exocrine differentiation within the same cell[1,2]. Diagnosis is mainly based on the tumor architecture, being completed by the immunostains with specific neuroendocrine markers such as chromogranin, synaptophysin, CD56, and neuron­specific enolase (NSE), combined with the markers on non­endocrine glandular component and slightly positive in the neuroendocrine areas (Figure 1). In the ascending colon, the glandular component represented about 40% of the tumor, being marked by keratin AE1/AE3, keratin 20, and CEA, without positivity for chromogranin, synaptophysin, NSE, and keratin 7. Ki67 proliferative index was < 20% (G2), without differences among the two components. Maspin expression was cytoplasmic in the glandular component and slightly positive in the neuroendocrine areas (Figure 1). In the ascending colon, an adenomatous polyp without dysplasia was associated.

The molecular examinations, performed with Roche’s LightCycler PCR­ and melting­point analysis, revealed a stable microsatellite status. MLH­1 and MSH­2 were positive in both tumor components.

Based on the tumor stage, a classical FOLFOX therapy was recommended. The postoperative course was uneventful, and to date, the patient has survived 10 mo without any evidence of recurrence or metastases.

Case 1
A 74­years­old female was admitted to the hospital with intestinal obstruction symptoms, and an emergency right hemicolectomy with terminal ileum resection was performed. Gross examination of the surgical specimen revealed a 70 mm × 18 mm polyoid tumor that produced obstruction of the cecum and presented direct invasion in the serosa of the transverse colon, without invasion in the appendix. The proximal and distal resected margins were free from tumor involvement. Histopathological examination of the surgical specimen confirmed the tumor infiltration of the transverse colon, without metastases in the 40 regional lymph nodes. Angiolympathic invasion, without perineural invasion, was also noted (pT4bN0 stage). The tumor architecture was predominantly (60% of tumor) solid, consisting of clusters of monomorphic tumor cells with abundant cytoplasm and large nuclei, marked by synaptophysin and NSE, which did not display positivity for keratin AE1/AE3, keratins 7/20, CEA, and chromogranin. A low mitotic activity was seen (< 20 mitoses/10 HPFs). Among these tumor clusters, moderately differentiated glandular structures with focal intraluminal Alcian blue­positive mucus were also seen. The glandular component represented about 40% of the tumor, being marked by keratin AE1/AE3, keratin 20, and CEA, without positivity for chromogranin, synaptophysin, NSE, and keratin 7. Ki67 proliferative index was < 20% (G2), without differences among the two components. Maspin expression was cytoplasmic in the glandular component and slightly positive in the neuroendocrine areas (Figure 1). In the ascending colon, an adenomatous polyp without dysplasia was associated.

The molecular examinations, performed with Roche’s LightCycler PCR­ and melting­point analysis, revealed a stable microsatellite status. MLH­1 and MSH­2 were positive in both tumor components.

Based on the tumor stage, a classical FOLFOX therapy was recommended. The postoperative course was uneventful, and to date, the patient has survived 10 mo without any evidence of recurrence or metastases.

Case 2
A 46­years­old male was admitted to the hospital with symptoms suggesting gastric cancer: weight loss, hematemesis and melena, without signs of carcinoid syndrome. On upper gastrointestinal endoscopy, a type I­Borrmann’s tumor was described in the antral region, which was surgically removed. Intraoperatively, direct invasion in the
pancreas was identified. Total gastrectomy with D2 lymphadenectomy was performed. Gross examination of the surgical specimen revealed a 70 mm × 80 mm polypoid antral tumor that produced direct invasion in the pancreas. The tumor invaded the distal resection margin. Histopathological examination of the surgical specimen confirmed the pancreatic invasion, and the presence of metastases in 22 of the 32 lymph nodes, with peri lymphonodular invasion; celiac and hepatic hilum lymph nodes presented metastases. Angiolymphatic and perineural invasions were also noted (pT4N3b stage). The tumor architecture was predominantly (60% of tumor) glandular, with moderately differentiated glandular structures, without mucinous component, marked by keratin AE1/AE3, keratin 7, and CEA, without positivity for chromogranin, synaptophysin, NSE, HER-2, keratin 20, and vimentin. Among the glandular structures, solid sheets, cords, and islands of monomorphic tumor cells with scant cytoplasm and large pleomorphic nuclei were seen; they were immunoreactive for synaptophysin and NSE, and did not display positivity for keratin AE1/AE3, keratins 7/20, chromogranin, HER-2, CEA, and vimentin. Mitotic activity was high (> 20 mitoses/10 HPFs). Ki67 proliferation index was 80% (G3), without differences among the two components. Maspin expression was nuclear in the glandular component and negative in the neuroendocrine areas (Figure 2). In the metastatic lymph nodes, the glandular component was predominant.

The molecular examinations, performed with Roche’s LightCycler PCR- and melting-point analysis, revealed a stable microsatellite status. MLH-1 and MSH-2 were positive in both components. The patient refused chemotherapy and died 5 mo after surgery.

DISCUSSION

The cecum MANEC was first described by Cardier in 1924, and another six cases have been reported later[3]. In the colorectal segments, independently by localization, a polypoid lesion has been reported arising in patients aged around 60 years, with the male/female ratio being about 1.5:1. All seven cases of cecum MANEC were reported in women. In majority of the cases, MANEC presents with an aggressive behavior and a high risk for liver metastases[3,4]. Independent from the proportion of the neuroendocrine component, the associated carcinoid syndrome was not reported yet in the literature; the serum level of tumor markers such as CEA, CA125, and CA19-9 are also normal[1]. The clinical behavior seems to be influenced by the neuroendocrine component[1]. However, identification of the neuroendocrine component in tubular adenocarcinomas is not easily performed because the neuroendocrine cells are not always immunoreactive for specific markers, with the reported rate of positivity being 60%-70% for chromogranin, 75%-90% for synaptophysin, and 50% for CD56[1,5,6]. In our case, the neuroendocrine component was diffusely positive for synaptophysin and negative for chromogranin. The cytoplasmic expression of maspin in the glandular structures indicates an indolent behavior of this component[7], it’s negativity in the neuroendocrine areas confirming that the clinical outcome depends on the characteristics of the neuroendocrine carcinoma. Angiolympathic invasion was noted in our cases without any lymph node metastases.

The reported clinicopathologic characteristics of gastric MANEC are similar with those of colorectal segments, the non-endocrine component being
rather an intestinal type rather than a diffuse-type gastric carcinoma. The mean age is 58 years old (range: 30 to 80 years old), and the polypoid lesions are usually located in upper, middle, or lower third of the stomach\[^{5}\]. Although some authors sustain that clinical behavior depends on the grade of the neuroendocrine component, some of them reveal that the characteristics of adenocarcinomatous part influence the outcome in well-differentiated neuroendocrine components\[^{6-8}\]. In our case, the glandular component was predominant in lymph node metastases and nuclear expression of maspin in glandular structures compared with its negativity in the neuroendocrine part confirmed the higher aggressiveness of the glandular part, compared to the poorly differentiated neuroendocrine one\[^{7}\].

Due to the rarity of this tumor, few aspects are known about its histogenesis, with most of the authors admitting its origin in a multipotent stem cell with bidirectional differentiation, opposite to collision tumor, in which a separate origin of the two components is supposed\[^{1-3,6}\]. Because the poorly differentiated areas can also display positivity for synaptophysin in colorectal carcinomas\[^9\], we tend to believe that it is not about a real multidirectional differentiation of a single neoplasm but rather a neuroendocrine phenotype of dedifferentiated areas of tubular adenocarcinoma. To sustain our hypothesis, it is necessary to also take into account the expression of CD133, the marker of cancer stem cells. Recently, it was reported that CD133 was expressed in 30% of well-differentiated neuroendocrine tumors, in 26% of poorly differentiated neuroendocrine carcinomas, and in 64% of MANEC of the digestive tract\[^{10}\]. On the other hand, the proportion of CD133 positivity in colorectal adenocarcinomas was 47%, without correlation with the tumor grade but with a strong correlation

Figure 2  Gastric mixed adenoneuroendocrine carcinoma consists of mixed proliferation of glandular with specific immunoexpression. Solid tumor areas (A); The glandular structures are reactive for keratin AE1/AE3 (B) and solid structures express synaptophysin (C); A high Ki67 index can be seen in both tumor components (D); The nuclear expression of maspin in the glandular component (E) reflects the tumor aggressiveness that is confirmed by predominance of this component in lymph node metastases (F).
with the tumor aggressiveness\textsuperscript{11}. In gastric adenocarcinoma, the CD133 positivity was 42%, being also correlated with the clinical outcome\textsuperscript{12}. Comparing the proportion of CD133 positivity, we can also support that the neuroendocrine component of MANEC, independent of its location, is rather a dedifferentiated area of a classic adenocarcinoma.

Clarifying this hypothesis could help identify of the proper therapeutic management of these rare, highly malignant tumors, similar to that of ordinary adenocarcinomas or for neuroendocrine tumors.

**REFERENCES**

1. Kitajima T, Kaida S, Lee S, Haruta S, Shinohara H, Ueno M, Soyama K, Oota Y, Fujii T, Udagawa H. Mixed adenono(neuro)endocrine carcinoma arising from the ectopic gastric mucosa of the upper thoracic esophagus. *World J Surg Oncol* 2013; 11: 218 [PMID: 24139488 DOI: 10.1186/1477-7819-11-218]

2. Faggioni R, Streiff EB. [Treatment of sequelae of corneal wounds]. *Acte Ther Clin Ophthalm* 1977; 28: 33-47 [PMID: 354488]

3. Jain A, Singla S, Jagdeesh KS, Vishnumurthy HY. Mixed adenoneuroendocrine carcinoma of cecum: a rare entity. *J Clin Imaging Sci* 2013; 3: 10 [PMID: 23607079 DOI: 10.4103/2156-7514.107995]

4. Ito H, Kado A, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka S, Tanabe M. Mixed adenoneuroendocrine carcinoma of the colon progressed rapidly after hepatic rupture: report of a case. *Int Surg* 2014; 99: 40-44 [PMID: 24444267 DOI: 10.9738/INTSURG-D-13-00161.1]

5. Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. *BMC Endocr Disord* 2012; 12: 30 [PMID: 23194346 DOI: 10.1186/1472-6823-12-30]

6. Kim JJ, Kim JY, Hur H, Cho YK, Han SU. Clinicopathologic significance of gastric adenocarcinoma with neuroendocrine features. *J Gastric Cancer* 2011; 11: 195-199 [PMID: 22324009 DOI: 10.5230/jgc.2011.11.4.195]

7. Gurzu S, Szentirmay Z, Popa D, Jung I. Practical value of the new system for Maspin assessment, in colorectal cancer. *Neoplasma* 2013; 60: 373-383 [PMID: 23581409 DOI: 10.4149/neo_2013_049]

8. Lee JH, Kim HW, Kang DH, Choi CW, Park SB, Kim SH. A gastric composite tumor with an adenocarcinoma and a neuroendocrine carcinoma: a case report. *Clin Endosc* 2013; 46: 280-283 [PMID: 23767040 DOI: 10.5946/ce.2013.46.3.280]

9. Gurzu S, Serester O, Jung I. Possible neuroendocrine phenotype of poorly differentiated cell clusters in colorectal carcinoma, as a prognostic parameter. *Am J Surg Pathol* 2014; 38: 143-144 [PMID: 24335644 DOI: 10.1097/PAS.0000000000000118]

10. Mia-Jan K, Munkhdelger J, Lee MR, Ji SY, Kang TY, Choi E, Cho MY. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis. *Tohoku J Exp Med* 2013; 229: 301-309 [PMID: 23615455 DOI: 10.1620/tjem.229.301]

11. Zhou F, Mu YD, Liang J, Liu ZX, Chen HS, Zhang JF. Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. *Oncol Lett* 2014; 7: 507-512 [PMID: 24396478 DOI: 10.3892/ol.2013.1723]

12. Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB, Cai MY. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. *J Surg Oncol* 2013; 107: 799-806 [PMID: 23609373 DOI: 10.1002/jso.23337]

P- Reviewer: Lorenzo-Zuniga V, Wang RZ  S- Editor: Qi Y  L- Editor: A  E- Editor: Wang CH
